Baidu
map

JCO:立体定向放射治疗加化疗可提高IV期肺癌患者的生存率

2015-01-04 zhangjialiang译 MedSci原创

UT西南医学中心的癌症研究人员报道,在一个结合立体定向放射治疗与特定的化疗方案临床试验中,IV期肺癌患者的生存率增加了一倍多。相比单用厄洛替尼治疗的仅仅6 - 9个月的生存时间,名为SBRT的体部立体定向放射治疗与化疗药厄洛替尼的结合,能够提高总生存时间至20个月。这种联合治疗能够延长患者无进展生存期,使相似的肺癌患者无进展生存期从以前的2-4个月延长至14.7个月。“我们的方法极大地改变了复发的

UT西南医学中心的癌症研究人员报道,在一个结合立体定向放射治疗与特定的化疗方案临床试验中,IV期肺癌患者的生存率增加了一倍多。 相比单用厄洛替尼治疗的仅仅6 - 9个月的生存时间,名为SBRT的体部立体定向放射治疗与化疗药厄洛替尼的结合,能够提高总生存时间至20个月。这种联合治疗能够延长患者无进展生存期,使相似的肺癌患者无进展生存期从以前的2-4个月延长至14.7个月。 “我们的方法极大地改变了复发的模式。我们看到的是在复发、转移方面的改变,”Annette Simmons立体定向治疗中心的主任、 UT西南医学中心的放射肿瘤学副主席、资深作者Dr. Robert Timmerman说,“这种转变导致癌症患者的经过更长时间才会再次出现肿瘤。” 据国家癌症研究所统计,在2014年期间估计有224210名男性和女性诊断为肺癌。来自2004年10月的数据显示,肺癌的五年相对生存率仍然较低,只有16.8%。而在这些癌症病例中,约有85%属于非小细胞肺癌的范畴。 这项II期临床试验包括24例IV期非小细胞肺癌(NSCLC)的癌症患者,他们在接受初始治疗期间即出现肿瘤的继续扩散。该研究的第一

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=93829, encodeId=49339382960, content=继续学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/bd34754d3b0046c2bd64321e47863622/81281d26ab254ed9803ad3323b1a5f2a.jpg, createdBy=0d5f1677558, createdName=yde2801fm***3926(暂无匿称), createdTime=Wed Jul 20 15:29:00 CST 2016, time=2016-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634360, encodeId=e10616343606a, content=<a href='/topic/show?id=5cd0e56034c' target=_blank style='color:#2F92EE;'>#立体定向放射治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75603, encryptionId=5cd0e56034c, topicName=立体定向放射治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98a622156602, createdName=xue8609, createdTime=Wed Nov 11 22:32:00 CST 2015, time=2015-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891159, encodeId=3555189115961, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Aug 23 11:32:00 CST 2015, time=2015-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986474, encodeId=5be019864e401, content=<a href='/topic/show?id=160be5596d3' target=_blank style='color:#2F92EE;'>#立体定向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75596, encryptionId=160be5596d3, topicName=立体定向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Mon Feb 02 10:32:00 CST 2015, time=2015-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768985, encodeId=43611e68985e9, content=<a href='/topic/show?id=d7674593e05' target=_blank style='color:#2F92EE;'>#定向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45937, encryptionId=d7674593e05, topicName=定向)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920637977772, createdName=liao1632, createdTime=Thu Feb 05 14:32:00 CST 2015, time=2015-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990537, encodeId=55a6199053e56, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Thu May 07 21:32:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13833, encodeId=36d313833c9, content=很好的文章,阐述了新的观点, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/27/fbd784adc68b967ee1f6d8d7192692c0.jpg, createdBy=771884322, createdName=zczcz6655, createdTime=Sat Jan 10 20:41:00 CST 2015, time=2015-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256501, encodeId=2bdc1256501c4, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Tue Jan 06 13:32:00 CST 2015, time=2015-01-06, status=1, ipAttribution=)]
    2016-07-20 yde2801fm***3926(暂无匿称)

    继续学习中

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=93829, encodeId=49339382960, content=继续学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/bd34754d3b0046c2bd64321e47863622/81281d26ab254ed9803ad3323b1a5f2a.jpg, createdBy=0d5f1677558, createdName=yde2801fm***3926(暂无匿称), createdTime=Wed Jul 20 15:29:00 CST 2016, time=2016-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634360, encodeId=e10616343606a, content=<a href='/topic/show?id=5cd0e56034c' target=_blank style='color:#2F92EE;'>#立体定向放射治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75603, encryptionId=5cd0e56034c, topicName=立体定向放射治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98a622156602, createdName=xue8609, createdTime=Wed Nov 11 22:32:00 CST 2015, time=2015-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891159, encodeId=3555189115961, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Aug 23 11:32:00 CST 2015, time=2015-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986474, encodeId=5be019864e401, content=<a href='/topic/show?id=160be5596d3' target=_blank style='color:#2F92EE;'>#立体定向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75596, encryptionId=160be5596d3, topicName=立体定向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Mon Feb 02 10:32:00 CST 2015, time=2015-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768985, encodeId=43611e68985e9, content=<a href='/topic/show?id=d7674593e05' target=_blank style='color:#2F92EE;'>#定向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45937, encryptionId=d7674593e05, topicName=定向)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920637977772, createdName=liao1632, createdTime=Thu Feb 05 14:32:00 CST 2015, time=2015-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990537, encodeId=55a6199053e56, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Thu May 07 21:32:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13833, encodeId=36d313833c9, content=很好的文章,阐述了新的观点, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/27/fbd784adc68b967ee1f6d8d7192692c0.jpg, createdBy=771884322, createdName=zczcz6655, createdTime=Sat Jan 10 20:41:00 CST 2015, time=2015-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256501, encodeId=2bdc1256501c4, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Tue Jan 06 13:32:00 CST 2015, time=2015-01-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=93829, encodeId=49339382960, content=继续学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/bd34754d3b0046c2bd64321e47863622/81281d26ab254ed9803ad3323b1a5f2a.jpg, createdBy=0d5f1677558, createdName=yde2801fm***3926(暂无匿称), createdTime=Wed Jul 20 15:29:00 CST 2016, time=2016-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634360, encodeId=e10616343606a, content=<a href='/topic/show?id=5cd0e56034c' target=_blank style='color:#2F92EE;'>#立体定向放射治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75603, encryptionId=5cd0e56034c, topicName=立体定向放射治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98a622156602, createdName=xue8609, createdTime=Wed Nov 11 22:32:00 CST 2015, time=2015-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891159, encodeId=3555189115961, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Aug 23 11:32:00 CST 2015, time=2015-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986474, encodeId=5be019864e401, content=<a href='/topic/show?id=160be5596d3' target=_blank style='color:#2F92EE;'>#立体定向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75596, encryptionId=160be5596d3, topicName=立体定向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Mon Feb 02 10:32:00 CST 2015, time=2015-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768985, encodeId=43611e68985e9, content=<a href='/topic/show?id=d7674593e05' target=_blank style='color:#2F92EE;'>#定向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45937, encryptionId=d7674593e05, topicName=定向)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920637977772, createdName=liao1632, createdTime=Thu Feb 05 14:32:00 CST 2015, time=2015-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990537, encodeId=55a6199053e56, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Thu May 07 21:32:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13833, encodeId=36d313833c9, content=很好的文章,阐述了新的观点, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/27/fbd784adc68b967ee1f6d8d7192692c0.jpg, createdBy=771884322, createdName=zczcz6655, createdTime=Sat Jan 10 20:41:00 CST 2015, time=2015-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256501, encodeId=2bdc1256501c4, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Tue Jan 06 13:32:00 CST 2015, time=2015-01-06, status=1, ipAttribution=)]
    2015-08-23 lidong40
  4. [GetPortalCommentsPageByObjectIdResponse(id=93829, encodeId=49339382960, content=继续学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/bd34754d3b0046c2bd64321e47863622/81281d26ab254ed9803ad3323b1a5f2a.jpg, createdBy=0d5f1677558, createdName=yde2801fm***3926(暂无匿称), createdTime=Wed Jul 20 15:29:00 CST 2016, time=2016-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634360, encodeId=e10616343606a, content=<a href='/topic/show?id=5cd0e56034c' target=_blank style='color:#2F92EE;'>#立体定向放射治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75603, encryptionId=5cd0e56034c, topicName=立体定向放射治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98a622156602, createdName=xue8609, createdTime=Wed Nov 11 22:32:00 CST 2015, time=2015-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891159, encodeId=3555189115961, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Aug 23 11:32:00 CST 2015, time=2015-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986474, encodeId=5be019864e401, content=<a href='/topic/show?id=160be5596d3' target=_blank style='color:#2F92EE;'>#立体定向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75596, encryptionId=160be5596d3, topicName=立体定向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Mon Feb 02 10:32:00 CST 2015, time=2015-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768985, encodeId=43611e68985e9, content=<a href='/topic/show?id=d7674593e05' target=_blank style='color:#2F92EE;'>#定向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45937, encryptionId=d7674593e05, topicName=定向)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920637977772, createdName=liao1632, createdTime=Thu Feb 05 14:32:00 CST 2015, time=2015-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990537, encodeId=55a6199053e56, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Thu May 07 21:32:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13833, encodeId=36d313833c9, content=很好的文章,阐述了新的观点, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/27/fbd784adc68b967ee1f6d8d7192692c0.jpg, createdBy=771884322, createdName=zczcz6655, createdTime=Sat Jan 10 20:41:00 CST 2015, time=2015-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256501, encodeId=2bdc1256501c4, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Tue Jan 06 13:32:00 CST 2015, time=2015-01-06, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=93829, encodeId=49339382960, content=继续学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/bd34754d3b0046c2bd64321e47863622/81281d26ab254ed9803ad3323b1a5f2a.jpg, createdBy=0d5f1677558, createdName=yde2801fm***3926(暂无匿称), createdTime=Wed Jul 20 15:29:00 CST 2016, time=2016-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634360, encodeId=e10616343606a, content=<a href='/topic/show?id=5cd0e56034c' target=_blank style='color:#2F92EE;'>#立体定向放射治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75603, encryptionId=5cd0e56034c, topicName=立体定向放射治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98a622156602, createdName=xue8609, createdTime=Wed Nov 11 22:32:00 CST 2015, time=2015-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891159, encodeId=3555189115961, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Aug 23 11:32:00 CST 2015, time=2015-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986474, encodeId=5be019864e401, content=<a href='/topic/show?id=160be5596d3' target=_blank style='color:#2F92EE;'>#立体定向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75596, encryptionId=160be5596d3, topicName=立体定向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Mon Feb 02 10:32:00 CST 2015, time=2015-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768985, encodeId=43611e68985e9, content=<a href='/topic/show?id=d7674593e05' target=_blank style='color:#2F92EE;'>#定向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45937, encryptionId=d7674593e05, topicName=定向)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920637977772, createdName=liao1632, createdTime=Thu Feb 05 14:32:00 CST 2015, time=2015-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990537, encodeId=55a6199053e56, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Thu May 07 21:32:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13833, encodeId=36d313833c9, content=很好的文章,阐述了新的观点, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/27/fbd784adc68b967ee1f6d8d7192692c0.jpg, createdBy=771884322, createdName=zczcz6655, createdTime=Sat Jan 10 20:41:00 CST 2015, time=2015-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256501, encodeId=2bdc1256501c4, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Tue Jan 06 13:32:00 CST 2015, time=2015-01-06, status=1, ipAttribution=)]
    2015-02-05 liao1632
  6. [GetPortalCommentsPageByObjectIdResponse(id=93829, encodeId=49339382960, content=继续学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/bd34754d3b0046c2bd64321e47863622/81281d26ab254ed9803ad3323b1a5f2a.jpg, createdBy=0d5f1677558, createdName=yde2801fm***3926(暂无匿称), createdTime=Wed Jul 20 15:29:00 CST 2016, time=2016-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634360, encodeId=e10616343606a, content=<a href='/topic/show?id=5cd0e56034c' target=_blank style='color:#2F92EE;'>#立体定向放射治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75603, encryptionId=5cd0e56034c, topicName=立体定向放射治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98a622156602, createdName=xue8609, createdTime=Wed Nov 11 22:32:00 CST 2015, time=2015-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891159, encodeId=3555189115961, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Aug 23 11:32:00 CST 2015, time=2015-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986474, encodeId=5be019864e401, content=<a href='/topic/show?id=160be5596d3' target=_blank style='color:#2F92EE;'>#立体定向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75596, encryptionId=160be5596d3, topicName=立体定向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Mon Feb 02 10:32:00 CST 2015, time=2015-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768985, encodeId=43611e68985e9, content=<a href='/topic/show?id=d7674593e05' target=_blank style='color:#2F92EE;'>#定向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45937, encryptionId=d7674593e05, topicName=定向)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920637977772, createdName=liao1632, createdTime=Thu Feb 05 14:32:00 CST 2015, time=2015-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990537, encodeId=55a6199053e56, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Thu May 07 21:32:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13833, encodeId=36d313833c9, content=很好的文章,阐述了新的观点, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/27/fbd784adc68b967ee1f6d8d7192692c0.jpg, createdBy=771884322, createdName=zczcz6655, createdTime=Sat Jan 10 20:41:00 CST 2015, time=2015-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256501, encodeId=2bdc1256501c4, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Tue Jan 06 13:32:00 CST 2015, time=2015-01-06, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=93829, encodeId=49339382960, content=继续学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/bd34754d3b0046c2bd64321e47863622/81281d26ab254ed9803ad3323b1a5f2a.jpg, createdBy=0d5f1677558, createdName=yde2801fm***3926(暂无匿称), createdTime=Wed Jul 20 15:29:00 CST 2016, time=2016-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634360, encodeId=e10616343606a, content=<a href='/topic/show?id=5cd0e56034c' target=_blank style='color:#2F92EE;'>#立体定向放射治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75603, encryptionId=5cd0e56034c, topicName=立体定向放射治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98a622156602, createdName=xue8609, createdTime=Wed Nov 11 22:32:00 CST 2015, time=2015-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891159, encodeId=3555189115961, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Aug 23 11:32:00 CST 2015, time=2015-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986474, encodeId=5be019864e401, content=<a href='/topic/show?id=160be5596d3' target=_blank style='color:#2F92EE;'>#立体定向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75596, encryptionId=160be5596d3, topicName=立体定向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Mon Feb 02 10:32:00 CST 2015, time=2015-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768985, encodeId=43611e68985e9, content=<a href='/topic/show?id=d7674593e05' target=_blank style='color:#2F92EE;'>#定向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45937, encryptionId=d7674593e05, topicName=定向)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920637977772, createdName=liao1632, createdTime=Thu Feb 05 14:32:00 CST 2015, time=2015-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990537, encodeId=55a6199053e56, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Thu May 07 21:32:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13833, encodeId=36d313833c9, content=很好的文章,阐述了新的观点, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/27/fbd784adc68b967ee1f6d8d7192692c0.jpg, createdBy=771884322, createdName=zczcz6655, createdTime=Sat Jan 10 20:41:00 CST 2015, time=2015-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256501, encodeId=2bdc1256501c4, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Tue Jan 06 13:32:00 CST 2015, time=2015-01-06, status=1, ipAttribution=)]
    2015-01-10 zczcz6655

    很好的文章,阐述了新的观点

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=93829, encodeId=49339382960, content=继续学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/bd34754d3b0046c2bd64321e47863622/81281d26ab254ed9803ad3323b1a5f2a.jpg, createdBy=0d5f1677558, createdName=yde2801fm***3926(暂无匿称), createdTime=Wed Jul 20 15:29:00 CST 2016, time=2016-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634360, encodeId=e10616343606a, content=<a href='/topic/show?id=5cd0e56034c' target=_blank style='color:#2F92EE;'>#立体定向放射治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75603, encryptionId=5cd0e56034c, topicName=立体定向放射治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98a622156602, createdName=xue8609, createdTime=Wed Nov 11 22:32:00 CST 2015, time=2015-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891159, encodeId=3555189115961, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Sun Aug 23 11:32:00 CST 2015, time=2015-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986474, encodeId=5be019864e401, content=<a href='/topic/show?id=160be5596d3' target=_blank style='color:#2F92EE;'>#立体定向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75596, encryptionId=160be5596d3, topicName=立体定向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Mon Feb 02 10:32:00 CST 2015, time=2015-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768985, encodeId=43611e68985e9, content=<a href='/topic/show?id=d7674593e05' target=_blank style='color:#2F92EE;'>#定向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45937, encryptionId=d7674593e05, topicName=定向)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920637977772, createdName=liao1632, createdTime=Thu Feb 05 14:32:00 CST 2015, time=2015-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990537, encodeId=55a6199053e56, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Thu May 07 21:32:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13833, encodeId=36d313833c9, content=很好的文章,阐述了新的观点, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/27/fbd784adc68b967ee1f6d8d7192692c0.jpg, createdBy=771884322, createdName=zczcz6655, createdTime=Sat Jan 10 20:41:00 CST 2015, time=2015-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256501, encodeId=2bdc1256501c4, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Tue Jan 06 13:32:00 CST 2015, time=2015-01-06, status=1, ipAttribution=)]

相关资讯

Frederik Wenz教授:立体定向放疗(SBRT)优于常规放疗

     Frederik Wenz教授   9月3-4日,第3届中德肺癌论坛在上海举行。在为期两天的论坛中,数十位国内外知名肺癌专家对2011年全球肺癌领域的学术热点、难点进行年度盘点,并和与会人士展开全面的交流和讨论。   德国曼海姆大学Frederik Wenz教授介绍了立体定向放疗在肺癌治疗中的进展。   杜克大学在20世纪90年代的经验提示,在非小细胞肺癌(N

Baidu
map
Baidu
map
Baidu
map